内容来源：https://www.geekwire.com/2025/seattle-biotech-startup-collaborates-with-eli-lilly-in-pursuit-of-therapy-for-solid-tumors/

内容总结：

【前沿生物科技公司Lila与制药巨头礼来联手开发实体瘤靶向疗法】
由诺贝尔化学奖得主David Baker实验室孵化的初创企业Lila Biologics近日宣布与跨国药企礼来（Eli Lilly）达成合作，共同开发针对实体瘤的创新疗法。这家仅7人的初创公司凭借其人工智能驱动的蛋白质设计技术，将专注于靶向放疗平台的开发，旨在设计能精准结合肿瘤并携带放射性同位素的蛋白质，以精确摧毁癌细胞。

Lila公司联合创始人兼CEO Jake Kraft表示，此次合作标志着其技术正式进入临床应用阶段。公司预计将在3至6个月内向礼来提供候选蛋白质分子，由后者推进临床试验。此外，Lila还同步开发了长效注射药物平台，可实现数周至数月的持续药物释放，目前已有治疗肺部疾病的候选药物进入临床前研究阶段。

David Baker教授领导的华盛顿大学蛋白质设计研究所是Lila的技术基石。其团队开发的AI工具能高效设计具有特定功能的全新蛋白质，相关成果已多次发表于顶级科学期刊。该研究所已向全球研究者免费开放其核心AI技术，以推动领域发展。

Lila于2023年完成1000万美元种子轮融资，由WRF Capital等机构领投。公司强调，其靶向疗法瞄准的是业界尚未攻克的复杂肿瘤靶点，致力于将实验室突破转化为挽救生命的实际疗法。

中文翻译：

由诺贝尔奖得主戴维·贝克在华盛顿大学的实验室孵化的初创企业莱拉生物公司宣布，将与制药巨头礼来公司合作开发实体瘤治疗方案。该公司还推出了两个由人工智能和机器学习驱动的治疗性蛋白质研发平台：一个专注于靶向放射治疗，通过生成能精准结合肿瘤并携带放射性同位素的蛋白质来消灭癌细胞；另一个平台用于构建长效注射药物，使药物能在数周或数月内持续释放。

这家仅有7名员工的初创企业将在与礼来的合作中运用其靶向放射治疗技术，预计在三至六个月内提交候选蛋白质分子，由礼来公司推进临床试验。首席执行官杰克·克拉夫特向媒体表示："与礼来的合作充分证明我们已具备成熟技术，我们拥有独特优势并准备好开发药物。"

克拉夫特与首席科学家阿宁迪亚·罗伊于2023年共同创立莱拉生物，二人曾同在贝克领导的华盛顿大学蛋白质设计研究所从事博士后研究。贝克在声明中称赞："凭借世界级团队和机器学习驱动的蛋白质设计整体方案，莱拉生物在推进新型肿瘤靶向放疗和长效注射药物临床转化方面具有独特优势。"

这位2022年诺贝尔化学奖得主作为公司联合创始人，其革命性技术使研究人员能运用人工智能和机器学习算法设计具有特定功能的全新蛋白质，例如靶向递送药物或降解环境污染物。该研究所的人工智能工具能高效创建实验室验证有效的功能性蛋白质，显著节省研发成本。近月来研究所已在顶级科学期刊发表多篇论文展示该技术实力，包括成功构建可精准结合疾病标志物的从头设计蛋白质，以及捕获难捕捉易变形分子的蛋白质技术。

研究所已向全球用户免费开放其核心人工智能技术平台。莱拉生物向媒体透露，公司2023年已完成由WRF Capital、SilverArc资本管理和Sahsen风投领投的1000万美元种子轮融资，Boom Capital、Alexandria风险投资、科律律师事务所、Pack风投等机构参与投资。

在与礼来的合作项目中，莱拉科学家正攻关比常规目标更难命中的肿瘤靶点。同时团队还在推进自主研发管线，包括治疗肺部疾病的长效注射药物。目前已有候选药物进入临床前阶段，正准备开展新药研究申报工作以启动人体临床试验。克拉夫特强调："我们的使命是为患者带来切实疗法，不仅要说'我们设计了蛋白质'，更要能宣告'我们拯救了生命'。"

英文来源：

Lila Biologics, a startup that spun out of Nobel Laureate David Baker’s lab at the University of Washington, announced a collaboration with pharmaceutical giant Eli Lilly to develop therapies for treating solid tumors.
Lila has also launched two platforms powered by artificial intelligence and machine learning for creating new therapeutic proteins. One is focused on targeted radiotherapy, generating proteins that precisely bind to tumors and carry radioactive isotopes that zap cancerous cells. The other platform is used to build long-acting injectable drugs that gradually release medicine over weeks or months.
The 7-person startup is using its targeted radiotherapy tool in the partnership with Eli Lilly. It hopes to hand off a candidate protein within three to six months so the pharmaceutical company can take the drug through clinical trials.
The Eli Lilly collaboration “really proves we’re ready for prime time,” CEO Jake Kraft told GeekWire. “We have something unique out there and we’re ready to develop medicines.”
Kraft and Chief Scientist Anindya Roy co-founded Lila in 2023. The two worked as postdoctoral fellows in the UW’s Institute for Protein Design, which is directed by Baker.
“With a world-class team and holistic approach to ML-driven protein design in place, Lila Biologics is uniquely suited to advance a new class of tumor-targeted radiotherapies and [long-acting injectable] medicines toward the clinic,” Baker said in a statement.
Baker, who won his Nobel last year in chemistry and is a Lila co-founder, helped create a technology that allows researchers to use AI and ML algorithms to engineer never-before-seen proteins designed to perform specific functions, such as drug delivery or destroying environmental pollutants.
The AI tools from the institute are increasingly successful at creating proteins that function as planned when tested in the lab, saving time and money. Researchers with the Institute for Protein Design in recent months have published papers in top scientific journals demonstrating the technology’s capabilities. That includes creating de novo proteins that bind precise disease markers and others that grab hold of difficult-to-capture, shapeshifting molecules.
The institute has made its foundational AI technology free and publicly available to users worldwide.
In 2023, Lila raised a $10 million seed round led by WRF Capital, SilverArc Capital Management, and Sahsen Ventures, with participation from Boom Capital, Alexandria Venture Investments, Cooley, Pack Ventures, and other private investors, the company told GeekWire.
For the project with Eli Lilly, Lila scientists are going after harder-to-hit tumor targets than most other organizations have pursued.
The team is additionally working on its own pipeline of therapies, including a long-acting injectable to treat pulmonary disease. Lila scientists have candidate-stage drugs and are preparing for investigational new drug studies, which lead to human clinical trials.
“We want to bring medicines to patients,” Kraft said. “We don’t want to just say we’ve designed a protein, but we actually want to be able to say we’ve saved lives.”